Main Image

  • Posted Monday March 30, 2020

TGen, a Genomic First Responder, ramps up testing against COVID-19 coronavirus

TGen’s infectious disease lab makes assisting Arizona’s public health its #1 priority; provides critically needed testing for Arizona in combating this global health threat

PHOENIX and FLAGSTAFF, Ariz. — March 30, 2020 — Since mid-January, the Translational Genomics Research Institute (TGen) has joined the world-wide effort to test for the SARS-CoV-2 virus causing the COVID-19 disease.  Acting as Genomic First Responders, TGen, an affiliate of City of Hope, is using advanced biomedical technologies to study this disease while also working to help establish a statewide tracking network for COVID-19.

In early March — after receiving Emergency Use Authorization (EUA) from the FDA for its genomic-based test — TGen began working with federal, state, county and tribal governments, private healthcare providers and others to expand testing for COVID-19 in Arizona; part of a concerted effort to get out in front of this global health threat.

TGen’s CLIA lab can now process up to 300 samples per day for its clinical testing.  In addition, TGen is receiving patient respiratory samples daily in cases where other lung diseases have been ruled out to get some idea of the general population incidence of the virus.  TGen is also conducting analysis of samples from suspected and symptomatic individuals for COVID-19 from select communities, including Native American communities; and special populations, such as long-term healthcare centers and even jail populations, to help provide support to these often-underserved groups who are most in need.

Finally, through TGen, Arizona is moving to establish a comprehensive public health testing program for high-risk but asymptomatic individuals, such as healthcare workers on the first line of defense in combatting this pandemic, who could be a dangerous reservoir for the virus.  In fact, high-risk asymptomatic individuals are more likely to contribute to the infection rates than symptomatic individuals, since symptomatic individuals are less likely to be out in public.  This approach being pioneered at TGen has many advantages and could benefit the healthcare system by:

  • Determining how widespread COVID-19 is within Arizona.
  • Identifying emerging hotspots as they occur.
  • Assisting in efforts to contain and prevent the disease.

TGen has increased testing capacity

Importantly, TGen tests were designed to not rely on the same “supply chain” as the federal government’s COVID-19 test kits. While this is an advantage for conducting the actual tests, TGen and other centers still face sample-collection issues, such as not having enough sample swabs.  Regardless, TGen has a robust capacity to conduct COVID-19 testing, which is being scaled up. And, performing tests in Arizona reduces the time to report back results, compared to having to send samples outside of the state for testing.

Importantly, TGen is not administering tests to the general public, but is analyzing samples from public-health and healthcare entities. Individuals who are concerned they might have the COVID-19 coronavirus should work with their doctors and healthcare providers.

“We are not only able to answer the call for the State of Arizona, but also for others, as well,” said Dr. Jeffrey Trent, President and Research Director of TGen. Following a decade as Scientific Director of the National Human Genome Research Institute at the National Institutes of Health (NIH), he founded non-profit TGen, headquartered in downtown Phoenix, in 2002 with the help of Arizona government agencies, the business community and private contributions. “TGen joins with the international scientific community and others in this battle to protect the health of people across Arizona and throughout the nation.”

TGen tests based on precision medicine

“We are constantly in pursuit of precision medicine, providing unparalleled capacity, accuracy and speed at a time when all of these qualities are essential in beating back the global health threat posed by emerging diseases like COVID-19,” said Dr. David Engelthaler, Co-Director of TGen’s Pathogen and Microbiome Division (infectious diseases) in Flagstaff.

To cover the initial costs of its efforts, TGen has received support of $100,000 each from: the non-profit NARBHA Institute, Blue Cross and Blue Shield of Arizona, and two private foundations — the Flinn Foundation and Virginia G. Piper Charitable Trust.  

Dr. Engelthaler explains TGen’s tests for COVID-19 in the latest TGen Talks podcast; click here.

To donate, please go to:

# # #

About TGen, an affiliate of City of Hope
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life-changing results. TGen is affiliated with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases:  This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by TGen. TGen is focused on helping patients with neurological disorders, cancer, diabetes and infectious diseases through cutting-edge translational research (the process of rapidly moving research toward patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and complex rare diseases in adults and children.  Working with collaborators in the scientific and medical communities worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: Follow TGen on FacebookLinkedIn and Twitter @TGen.

Media Contact:
Steve Yozwiak
TGen Senior Science Writer
o. 602-343-8704
c. 602-620-4749
[email protected]

Media Contact

RSS Feed